{"id":"W3213050308","doi":"10.1182/bloodadvances.2021005794","title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Bendamustine; Hazard ratio; Internal medicine; Cohort; Confidence interval; Rituximab; Clinical endpoint; Randomized controlled trial; Oncology; Surgery; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001373225,0.0002073554,0.000500733,0.00006748074,0.00006925497,0.00003379288,0.00007915832,0.00007560234,0.00003816787],"category_scores_gemma":[0.0002383379,0.0001728412,0.00002688781,0.0001616408,0.00006908099,0.0002378883,0.0002540062,0.0001334055,0.00001016231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005312185,"about_ca_system_score_gemma":0.0002884361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003084796,"about_ca_topic_score_gemma":0.0006714252,"domain_scores_codex":[0.9985003,0.0000491582,0.0002816886,0.000680273,0.0002379687,0.0002506375],"domain_scores_gemma":[0.9989121,0.000154871,0.00008082962,0.0005850638,0.00005139393,0.0002157691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00042414,0.004278649,0.8411232,0.0002022741,0.0002680381,0.00311029,0.0001853373,0.000004749207,0.001224566,0.0004935824,0.0008404733,0.1478447],"study_design_scores_gemma":[0.04240524,0.0003515664,0.8882309,0.0004726199,0.0006642112,0.0005638583,0.000346644,0.0002097153,0.002367157,0.0002995642,0.06377602,0.0003125065],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8902329,0.1074911,0.00001052886,0.001293846,0.0002182242,0.0002348273,0.00005904029,0.00003840905,0.0004211114],"genre_scores_gemma":[0.9681491,0.02636807,0.004200771,0.0003494575,0.000198838,0.000009677098,0.0004391072,0.00002505243,0.0002599774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1475322,"threshold_uncertainty_score":0.7048258,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03337199370905094,"score_gpt":0.2962263346243567,"score_spread":0.2628543409153058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}